Back

Samsung Biologics target price cut 5% after ₩3 trillion rights offering

Verifying
  • DS Investment & Securities maintained Buy on Samsung Biologics and reduced its target price.
  • The brokerage cut its target by about 5%, from ₩1.95 million to ₩1.85 million.
  • Samsung Biologics announced the ₩3 trillion rights offering on August 28.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.